International validation of the revised European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQ‐HN43: Phase IV

Susanne Singer(Johannes Gutenberg University Mainz), Cecilie Delphin Amdal(Oslo University Hospital), Eva Hammerlid(Sahlgrenska University Hospital), Iwona M. Tomaszewska(Jagiellonian University), Joaquim Castro Silva(Instituto Português de Oncologia Francisco Gentil), Hisham Mehanna(University of Birmingham), M.A. Santos(Hospital Universitário de Brasília), Johanna Inhestern(Jena University Hospital), Christine Brannan(Mount Vernon Cancer Centre), Noam Yarom(Tel Aviv University), Amy Fullerton(University of Florida Health), Monica Pinto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Juan Ignacio Arrarás(Complejo Hospitalario de Navarra), Naomi Kiyota(Kobe University Hospital), Pierluigi Bonomo(Azienda Ospedaliero-Universitaria Careggi), Allen C. Sherman(Winthrop Rockefeller Foundation), Ingo Baumann(Heidelberg University), Razvan Galalae(Evangelische Kliniken Gelsenkirchen), Loreto Fernández‐González(Fundación Arturo López Pérez), Ourania Nicolatou‐Galitis(National and Kapodistrian University of Athens), Zeinab Mohamed Abdel-Hafeez(Ain Shams University), Judith E. Raber‐Durlacher(Amsterdam University Medical Centers), Claudia Schmalz(University Hospital Schleswig-Holstein), Paola Zotti(Centro di Riferimento Oncologico), Andreas Boehm(Klinikum St. Georg), Dirk Hofmeister(University Hospital Leipzig), Sanja Krejovic Trivic(University of Belgrade), Suat Loo(Colchester Hospital), Wei‐Chu Chie(National Taiwan University), Kristin Bjordal(Oslo University Hospital), Bente Brokstad Herlofson(Oslo University Hospital), Vincent Grégoire(UCLouvain), Lisa Licitra(University of Milan), on behalf of the EORTC Quality of Life and the EORTC Head and Neck Cancer Groups
Head & Neck
January 12, 2019
Cited by 138Open Access
Full Text

Abstract

BACKGROUND: We validated the new European Organisation for Research and Treatment of Cancer Quality of Life Head and Neck Module (EORTC QLQ-HN43). METHODS: We enrolled 812 patients with head and neck cancer from 18 countries. Group 1 completed the questionnaire before therapy, and 3 and 6 months later. In group 2 (survivors), we determined test-retest reliability using intraclass correlation coefficients (ICC). Internal consistency was assessed using Cronbach's Alpha, the scale structure with confirmatory factor analysis, and discriminant validity with known-group comparisons. RESULTS: Cronbach's alpha was >0.70 in 10 of the 12 multi-item scales. All standardized factor loadings exceeded 0.40. The ICC was >0.70 in all but two scales. Differences in scale scores between known-groups were >10 points in 17 of the 19 scales. Sensitivity to change was found to be sufficient in 18 scales. CONCLUSIONS: Evidence supports the reliability and validity of the EORTC QLQ-HN43 as a measure of quality of life.


Related Papers

No related papers found

Powered by citation graph analysis